NCT02363868已完成不适用
Costs and Outcome Among Patients With Chronic Myelogenous Leukemia (CML) Receiving Dasatinib or Nilotinib as First or Second Line Therapy in a Commercial and Medicare Population
Bristol-Myers Squibb1 个研究点 分布在 1 个国家目标入组 186 人开始时间: 2014年2月最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 186
- 试验地点
- 1
- 主要终点
- Healthcare costs
研究概览
简要总结
The purpose of this study is to examine the healthcare costs among patients with CML receiving dasatinib or nilotinib as first line therapy in a commercially or Medicare insured population.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age >18 years
- •International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9 CM) code for CML (205.1x)
- •At least 2 prescriptions for dasatinib or nilotinib from July 1, 2008 to June 31, 2013
- •Continuous eligibility for the 6 months pre- and post-index date (defined as the date of first fill for dasatinib or nilotinib)
排除标准
- •History of bone marrow or stem cell transplant as identified in the 6 month pre-period
结局指标
主要结局
Healthcare costs
时间窗: Intent-to-treat (ITT) at 6 months
Average (mean) costs for patients receiving dasatinib or nilotinib as first line therapy
次要结局
- Healthcare costs by line of therapy(Intent-to-treat (ITT) at 6 months)
- Resource utilization by line of therapy(Intent-to-treat (ITT) at 6 months)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Survey of Medical Cost and Livelihood of CML PatientsCMJPRN-UMIN000016522onprofit Organization, Japan Clinical Research Support Unit
Unknown
不适用
Symptom Burden in Chronic Myeloid Leukemia (CML)LeukemiaNCT01046305M.D. Anderson Cancer Center210
已完成
不适用
Patient Reported Outcomes in Chronic Myeloid LeukemiaChronic Myeloid LeukemiaNCT01252589Gruppo Italiano Malattie EMatologiche dell'Adulto480
已完成
不适用
Clinical Characteristics and Disease Burden of Diabetic Patients Based on Tianjin Regional DatabaseDiabetesNCT04903496Boehringer Ingelheim1,233,162
已完成
不适用
Economic Outcomes of EQW (Exenatide Once Weekly) vs. IG (Insulin Glargine) in T2D Patients Who Are New to Injectable TherapyDiabetes Mellitus Type 2NCT02843399AstraZeneca15,498